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We haveinvestigateddihydropyrimidine dehydrogenase expressionas aprognostic marker inbreastcancer. Atotalof 119women
withbreastcancerundergoingsurgerybetween1985and1996wereincludedinthisstudy.Eighty-sevenpatientsweretreatedwith
postoperativechemotherapyincluding5-ﬂuorouracilor5-ﬂuorouracilderivatives.Fifty-nine(50%)of119patientsweredetermined
to be immunostaining-positive for dihydropyrimidine dehydrogenase. There was no signiﬁcant difference between
dihydropyrimidine dehydrogenase staining and tumour size, lymph node status, clinical stage, oestrogen receptor status, histologic
grade,or5-ﬂuorouracil administration. Whenevaluated inpatientstreatedwith 5-ﬂuorouracilor5-ﬂuorouracilderivatives, patients
with dihydropyrimidine dehydrogenase-positive tumours had a signiﬁcantly (P50.05) poorer disease-free survival compared to
those with dihydropyrimidine dehydrogenase-negative tumour. No conclusion can be drawn about the prognostic impact of
dihydropyrimidine dehydrogenase status in patients who were not treated with 5-ﬂuorouracil regimes due to the small number of
suchcasesinthisseries.Lymphnodeanddihydropyrimidinedehydrogenasestatuswereindependentprognosticfactorsfordisease-
freesurvival,andlymphnodestatusforoverallsurvivalusingmultivariateanalysis.Inconclusion,dihydropyrimidinedehydrogenaseis
a possible prognostic factor in patients with breast cancer treated with 5-ﬂuorouracil or 5-ﬂuorouracil derivatives.
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5-ﬂuorouracil (5-FU) has been widely used in the treatment of breast
cancer, either singly or in combination with other cytostatics. 5-FU is
initially catabolized to 5-ﬂuorodihydrouracil by dihydropyrimidine
dehydrogenase (DPD), mainly in the liver, and then dihydropyrimi-
dinase and b-ureido-propionase catalyze the formation of 2-ﬂuoro-
b-alanine. More than 80% of an administered dose of 5-FU is elimi-
nated by catabolism through DPD (Milano and McLeod, 2000). A
high level of tumoral DPD metabolizes 5-FU to inactive products
before cytotoxic nucleotides can be formed. Although resistance to
5-FU is multifactorial, tumoral DPD activity may inﬂuence the efﬁ-
cacy of 5-FU. Several studies have demonstrated that high DPD
levels result in low sensitivity to 5-FU (Ishikawa et al, 2000; Salonga
et al, 2000; Inada et al, 2000; Mizutani et al, 2001).
Immunohistochemistry has the advantage of permitting the
evaluation of protein expression in situ using parafﬁn-embedded
blocks of specimens. There are only a few publications which
discuss immunohistochemical evaluation of DPD levels (Huang
et al, 2000; Miyamoto et al, 2000; Takenoue et al, 2000).
Takenoue et al (2000) investigated DPD expression using immuno-
histochemistry in colon carcinoma, and demonstrated that
immunohistochemical score was correlated with protein levels of
DPD.
In this study, we performed an immunohistochemical study of
intratumoral DPD expression in breast cancer, and examined the
prognostic and predictive signiﬁcance of DPD expression in breast
cancer patients.
PATIENTS AND METHODS
A total of 119 women with breast cancer undergoing surgery
between 1985 and 1996 were studied. The age at the time of surgery
ranged from 30 to 85 years (median, 51). Pathological examination
revealed that axillary lymph node status was positive in 56 patients
and negative in 63. The tumour size of the resected specimen was
2 cm or less in 23 patients and larger than 2 cm in 96 patients.
Oestrogen receptor (ER) content of tumours was measured using
an enzyme immunosorbent assay. Of 119 patients, 44 were ER-posi-
tive, 62 were ER-negative, and 13 were ER-unknown. Histologic
grading was performed by combining cell morphology, tissue archi-
tecture, and assessment of the cell proliferation rate (Bloom and
Richardson, 1957). Histologic grade was known for 116 patients
with invasive breast carcinomas. Thirty-two patients (28%) grade
I, 57 (49%) had grade II and 27 (23%) had grade III tumours. 5-
FU-based chemotherapy was administered to patients with vascular
invasion-positive tumours in the 1980s and all patients in the 1990s.
Eighty-seven patients were treated with postoperative chemotherapy
including 5-FU or 5-FU derivatives. Sixty-four patients received
20 mg of tamoxifen for at least 2 years. Immunohistochemical
examination was conducted using 4 mm of sections taken from
formalin-ﬁxed, parafﬁn-embedded blocks. Immunostaining was
performed on the sections using an Envision system (Dako Japan
Co., Kyoto). After deparafﬁnization with xylene and hydration with
downgraded ethanol, the sections were incubated in 0.3% H2O2 in
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www.bjcancer.commethanol for 5 min at room temperature. The rhDPD polyclonal
antibody (generously supplied by Dr Fukushima, Taiho Pharmaceu-
tical Co., Ltd.) was used as a primary antibody.
This is an antibody highly speciﬁc against rhDPD expressed in the
baculovirus-expression system using human DPD cDNA. The
expressed rhDPD protein has been found to retain the entire molecu-
larformandtoshowahigh5-FU-degradingactivityequivalenttothat
of the human liver DPD. Using this recombinant protein, polyclonal
antibodywasgeneratedandinvestigatedforitsspeciﬁcity,relationship
to enzyme activity and the possibility of immunohistochemical
measurement of tumoral DPD. The polyclonal antibody reacted with
both human and rodent DPD. Tumour cells expressing high levels of
DPD showed strongly positive staining, but those expressing low level
or no DPD showed no staining (Okabe et al, 2000). The sections were
rinsed with a buffer solution, and peroxidase labelled polymer was
incubated for 30 min at room temperature. After the sections were
washed with a buffersolution, the peroxidase reaction developed with
diaminobenzidine tetrahydrochloride, and nuclei were counter-
stained with haematoxylin. DPD staining was noted in the
cytoplasm of the cancer cells. DPD staining results were classiﬁed into
four grades (0: no staining, 1: weak, 2: intermediate, and 3: strong)
according to the intensity (Figure 1A, B, C and D). Immunostaining
of grades 0 and 1 was determined as DPD negative and grades 2 and
3 as positive. MIAPaCa-2 cells were used as positive control.
RESULTS
Of the 119 patients evaluated, 59 (50%) of 119 patients showed
immunostaining-positive for DPD. There was no signiﬁcant differ-
ence between DPD staining and tumour size, lymph node status,
clinical stage, ER status, histologic grade, or 5-FU and/or tamoxifen
administration (Table 1). The follow-up period ranged from 5 to
126 months (median 66 months). Actuarial disease-free survival
and overall survival were calculated using the Kaplan-Meier meth-
od. Patients with DPD-positive tumours had a signiﬁcantly
(P50.05) poorer prognosis in disease-free survival and overall
survival compared to those with DPD-negative tumours (Figures
2 and 3). When evaluated in patients treated with 5-FU or 5-FU
derivatives, DPD expression was a signiﬁcantly (P50.05) poorer
prognostic factor in disease-free survival (Figure 4). The small
number of cases in this series who were not given 5-FU based
chemotherapy means that no conclusion can be drawn about the
prognostic effect of DPD status in this group of better prognostic
patients. Multivariate analysis demonstrated that DPD and lymph
node status were independent prognostic factors for disease-free
survival. Lymph node status was an independent prognostic factor
for overall survival. (Tables 2 and 3).
DISCUSSION
DPD demonstrates variable activity in human tumours and the
variation in tumoral DPD may inﬂuence the efﬁcacy of 5-FU. A
signiﬁcant linear correlation has been observed between DPD activ-
ity and 5-FU clearance in patients with head and neck cancer while
simultaneously monitoring 5-FU pharmacokinetics during a 5-day,
continuous infusion 5-FU therapy (Fleming et al, 1992). Tumoral
DPD is associated with tumour response to 5-FU in patients with
gastric cancer (Inada et al, 2000; Ishikawa et al, 2000), colorectal
C
l
i
n
i
c
a
l
AB
CD
Figure 1 Immunohistochemical staining for DPD. (A) Grade 0 (no staining), (B) grade 2 (weak), (C) grade 3 (intermediate), (D) grade 3 (strong).
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(2), 222–225cancer (Salonga et al, 2000), or bladder cancer (Mizutani et al,
2001). Little is known about the relationship between DPD level
and cancer characteristics. Mizutani et al (2001) evaluated DPD
activity in bladder cancer. The levels of DPD activity in grade 2
and grade 3 bladder cancers were approximately three-fold and
four-fold higher than that in grade 1 cancers, respectively (Mizuta-
ni et al, 2001). Our study however did not show any relationship
between DPD level and clinicopathological factors including histo-
logic grade breast cancer. Takabayashi et al (2000) reported that
neither tumour depth nor lymph node metastases was correlated
with DPD activity in patients with gastric cancer. Huang et al
(2000) also reported no correlation between intratumoral DPD
staining and tumour status, nodal status, smoking habits, tumour
differentiation and tumour histology in non-small cell lung cancer.
The prognostic signiﬁcance of DPD expression in breast cancer
has not been completely investigated. Huang et al (2000) evaluated
intratumoral expression of DPD in non-small cell lung cancer
immunohistochemically, and the 5-year survival rate of patients
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Table 1 Patient characteristics
DPD expression
Negative Positive
(n=60) (n=59) P
Tumour size
2c m 5 16 7
2c m 5 44 52 NS
LN metastasis
03 7 2 6
1–3 10 20
4–9 11 9
104 24 N S
Stage
03 0
I1 1 5
II 34 43
III 12 11 NS
Oestrogen receptor
Negative 32 30
Positive 20 24
Unknown 8 5 NS
Histologic grade
I1 6 1 6
II 28 29
III 13 14 NS
Not classiﬁed 3 0
5-FU and/or TAM administration
No 17 10
TAM only 3 2
5-FU only 16 12
5-FU+TAM 24 35 NS
TAM: tamoxifen.
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Figure 2 Disease-free survival by DPD expression. Patients with DPD-
positive tumour had a signiﬁcantly (P50.05) poorer disease-free survival
than those with DPD-negative tumour.
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Figure 3 Overall survival by DPD expression. Patients with DPD-posi-
tive tumour had a signiﬁcantly (P50.05) poorer overall survival than those
with DPD-negative tumour.
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Figure 4 Disease-free survival by DPD expression in patients treated
with 5-FU or 5-FU derivatives. Patients with DPD-positive tumour had
signiﬁcantly (P50.05) poorer disease-free survival than those with DPD-
negative tumour in patients treated with 5-FU or 5-FU derivatives.
Table 2 Multivariate analysis for disease-free survival
Variables Coefﬁent s.e. w
2 P Risk ratio
Nodal status 71.254 0.358 12.268 0.001 0.285
ER 0.510 0.318 2.567 0.109 1.665
DPD 70.690 0.333 4.285 0.038 0.502
5-FU 70.216 0.429 0.254 0.614 0.806
Table 3 Multivariate analysis for overall survival
Variables Coefﬁcient s.e. w
2 P Risk ratio
Nodal status 72.103 0.501 17.623 50.0001 0.122
ER 0.583 0.349 2.781 0.095 1.791
DPD 70.464 0.356 1.706 0.192 0.629
5-FU 70.063 0.499 0.016 0.899 0.939
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British Journal of Cancer (2002) 86(2), 222–225 ã 2002 The Cancer Research Campaignwith high-DPD tumours was signiﬁcantly lower than for patients
with low-DPD tumours. Our immunohistochemical study clariﬁed
the prognostic signiﬁcance of the DPD expression in breast cancer.
Although DPD has the highest activity in liver and mononuclear
cells, DPD expression in tumours has demonstrated itself to be a
useful marker for disease-free survival in breast cancer patients
treated with 5-FU-based chemotherapy. Even if DPD activity in
the liver is low, a high level of tumour DPD would metabolise
5-FU to inactive products before cytotoxic nucleotides could be
formed. On the other hand, DPD expression showed no prognostic
function in patients who received no 5-FU-based chemotherapy.
The number of patients evaluated was too small to preclude the
prognostic function of DPD in patients who received no 5-FU-
based chemotherapy. Moreover, the patients who received no 5-
FU-based chemotherapy showed good prognosis irrespective of
DPD levels, since the patients with vascular invasion-negative
tumours were not treated with 5-FU-based chemotherapy in
follow-up.
DPD inhibition has become a major goal in the strategy for the
development of 5-FU treatment. A new antitumour agent based on
biochemical modulation of 5-FU (S-1), consisting of tegafur (FT),
5-chloro-2, 4-dihydroxypyridine (CDHP), and potassium oxonate
(Oxo) in a molar ratio of 1:0.4:1 has recently been developed (Shir-
asaka et al, 1996; Hirata et al, 1999). FT is a prodrug of 5-FU, and
CDHP competitively inhibits DPD about 180 times more effec-
tively than uracil, and leads to the retention of a prolonged
concentration of 5-FU. 5-FU or its derivatives used in this study
did not improve the prognosis of patients with DPD-positive
tumours. Our results suggest that a strong DPD inhibitor with
5-FU based chemotherapy, for example S-1 treatment, should be
considered to improve the prognosis of breast cancer patients with
DPD-positive tumours.
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